The FDA has approved an option to increase the dose and frequency of burosumab-twza for adults whose serum phosphorus remains below normal.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/new-dosing-option-okayed-x-linked-hypophosphatemia-drug-2026a1000g2u?src=rss
Author :
Publish date : 2026-05-18 19:04:00
Copyright for syndicated content belongs to the linked Source.
